Loading…
192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery
BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relative...
Saved in:
Published in: | Journal for immunotherapy of cancer 2021-11, Vol.9 (Suppl 2), p.A204-A204 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Request full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | A204 |
container_issue | Suppl 2 |
container_start_page | A204 |
container_title | Journal for immunotherapy of cancer |
container_volume | 9 |
creator | Reid, Jack Zhang, Shihong Munkhbat, Ariunaa Ecsedi, Matyas McAfee, Megan Chapuis, Aude |
description | BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a |
doi_str_mv | 10.1136/jitc-2021-SITC2021.192 |
format | article |
fullrecord | <record><control><sourceid>proquest_9YT</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_71557fd840694119bc0c6ca7711bec75</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_71557fd840694119bc0c6ca7711bec75</doaj_id><sourcerecordid>2595870566</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1852-41eba7e8455f13c82a4eb80501499b2ea3ed1c01816d9f434943fe9b12746b193</originalsourceid><addsrcrecordid>eNpFkdtq3DAQhk0h0JDkFYqgNw3UqUYHW7oMSw4LgYTGvRY6jNcy3tVWtgO5y01ftE8Sb7elVxrENz8z8xXFJ6BXALz61sfJl4wyKJ_XzepQXIFmH4pTRiWUIFj1sbgYx55SCpRzpdRpERfi99uvp5QGDKQhHoeBZPS4n1Imo8-Iu7jbkC9Pj83zJdnn9BIDjmTeuWhHDF9JFzddOXU5zZtuP09ki1OXAmmX9mb1nYQ4-vSC-fW8OGntMOLF3_es-HF706zuy4fHu_Xq-qF0oCQrBaCzNSohZQvcK2YFOkUlBaG1Y2g5BvAUFFRBt4ILLXiL2gGrReVA87NifcwNyfZmn-PW5leTbDR_PlLeGJun6Ac0NUhZt0EJWmkBoJ2nvvK2rgEc-louWZ-PWcveP2ccJ9OnOe-W8Q2TWqqayqpaKHak3Lb_DwA1ByvmYMUcZJh_Vsxyc_4O6GKB7g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595870566</pqid></control><display><type>article</type><title>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</title><source>BMJ Open Access Journals</source><creator>Reid, Jack ; Zhang, Shihong ; Munkhbat, Ariunaa ; Ecsedi, Matyas ; McAfee, Megan ; Chapuis, Aude</creator><creatorcontrib>Reid, Jack ; Zhang, Shihong ; Munkhbat, Ariunaa ; Ecsedi, Matyas ; McAfee, Megan ; Chapuis, Aude</creatorcontrib><description>BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a mouse model to screen for the most functional and physiologically fit TCR for cancer treatment.</description><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1136/jitc-2021-SITC2021.192</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Antigens ; Immunotherapy ; Lymphocytes ; Peptides ; Regular and Young Investigator Award Abstracts ; T cell receptors</subject><ispartof>Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A204-A204</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2595870566/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2595870566?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,55350,75126,77660,77686</link.rule.ids><linktorsrc>$$Uhttps://jitc.bmj.com/content/9/Suppl_2/A204.full$$EView_record_in_BMJ_Publishing_Group_Ltd$$FView_record_in_$$GBMJ_Publishing_Group_Ltd</linktorsrc></links><search><creatorcontrib>Reid, Jack</creatorcontrib><creatorcontrib>Zhang, Shihong</creatorcontrib><creatorcontrib>Munkhbat, Ariunaa</creatorcontrib><creatorcontrib>Ecsedi, Matyas</creatorcontrib><creatorcontrib>McAfee, Megan</creatorcontrib><creatorcontrib>Chapuis, Aude</creatorcontrib><title>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</title><title>Journal for immunotherapy of cancer</title><addtitle>J Immunother Cancer</addtitle><description>BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a mouse model to screen for the most functional and physiologically fit TCR for cancer treatment.</description><subject>Antigens</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Peptides</subject><subject>Regular and Young Investigator Award Abstracts</subject><subject>T cell receptors</subject><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpFkdtq3DAQhk0h0JDkFYqgNw3UqUYHW7oMSw4LgYTGvRY6jNcy3tVWtgO5y01ftE8Sb7elVxrENz8z8xXFJ6BXALz61sfJl4wyKJ_XzepQXIFmH4pTRiWUIFj1sbgYx55SCpRzpdRpERfi99uvp5QGDKQhHoeBZPS4n1Imo8-Iu7jbkC9Pj83zJdnn9BIDjmTeuWhHDF9JFzddOXU5zZtuP09ki1OXAmmX9mb1nYQ4-vSC-fW8OGntMOLF3_es-HF706zuy4fHu_Xq-qF0oCQrBaCzNSohZQvcK2YFOkUlBaG1Y2g5BvAUFFRBt4ILLXiL2gGrReVA87NifcwNyfZmn-PW5leTbDR_PlLeGJun6Ac0NUhZt0EJWmkBoJ2nvvK2rgEc-louWZ-PWcveP2ccJ9OnOe-W8Q2TWqqayqpaKHak3Lb_DwA1ByvmYMUcZJh_Vsxyc_4O6GKB7g</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Reid, Jack</creator><creator>Zhang, Shihong</creator><creator>Munkhbat, Ariunaa</creator><creator>Ecsedi, Matyas</creator><creator>McAfee, Megan</creator><creator>Chapuis, Aude</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20211101</creationdate><title>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</title><author>Reid, Jack ; Zhang, Shihong ; Munkhbat, Ariunaa ; Ecsedi, Matyas ; McAfee, Megan ; Chapuis, Aude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1852-41eba7e8455f13c82a4eb80501499b2ea3ed1c01816d9f434943fe9b12746b193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Peptides</topic><topic>Regular and Young Investigator Award Abstracts</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reid, Jack</creatorcontrib><creatorcontrib>Zhang, Shihong</creatorcontrib><creatorcontrib>Munkhbat, Ariunaa</creatorcontrib><creatorcontrib>Ecsedi, Matyas</creatorcontrib><creatorcontrib>McAfee, Megan</creatorcontrib><creatorcontrib>Chapuis, Aude</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Reid, Jack</au><au>Zhang, Shihong</au><au>Munkhbat, Ariunaa</au><au>Ecsedi, Matyas</au><au>McAfee, Megan</au><au>Chapuis, Aude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><stitle>J Immunother Cancer</stitle><date>2021-11-01</date><risdate>2021</risdate><volume>9</volume><issue>Suppl 2</issue><spage>A204</spage><epage>A204</epage><pages>A204-A204</pages><eissn>2051-1426</eissn><abstract>BackgroundT Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis and screening of individual TCRs based on tetramer binding and peptide specificity, which is costly and labor intensive. We have developed and validated a pooled approach relying on directly cloned TCRs transduced into a fluorescent Jurkat reporter system (figure 1). This approach provides an unbiased, high-throughput method for TCR discovery.MethodsAs a model for POTS, T cells specific for a peptide derived adenovirus structural protein were sorted on tetramer and subjected to 10x single cell VDJ analysis. Pools of randomly paired TCR alpha and beta chains were cloned from the 10x cDNA into a lentiviral vector and transduced into a Jurkat reporter cells. Consecutive stimulations with cognate antigen followed by cell sorts were performed to enrich for functional TCRs. Full length TCRab pools were sequenced by Oxford Nanopore Technologies (ONT) and compared to a 10x dataset to find naturally paired TCRs.ResultsComparison between the ex vivo single cell VDJ sequencing and ONT sequencing of the transduced antigen specific TCRs showed more than 99% of the TCR pairs found in reporter positive Jurkat cells were naturally paired TCRs. The functionality of 8 TCR clonotypes discovered using POTS were compared and clone #2 showed the strongest response. Of the selected clonotypes, clone #2 showed a low frequency of 0.9% in the ex vivo single cell VDJ sequencing. After the first round of stimulation and sequencing, clone #2 takes up of 5% of all reporter-positive clones. The abundance of clone #2 further increased to 17% after another round of stimulation, sorting and sequencing, suggesting this method can retrieve and enrich for highly functional antigen specific TCRs.Abstract 192 Figure 1Outline of the POTS workflow.ConclusionsPOTS provides a high-throughput method for discovery of naturally paired, high-avidity T cell receptors. This method mitigates bias introduced by T cell differentiation state by screening TCRs in a clonal reporter system. Additionally, POTS allows for screening of low abundance clones when compared with traditional TCR discovery techniques. Pooled TCRs could also be screened in vivo with primary T cells in a mouse model to screen for the most functional and physiologically fit TCR for cancer treatment.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><doi>10.1136/jitc-2021-SITC2021.192</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | EISSN: 2051-1426 |
ispartof | Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A204-A204 |
issn | 2051-1426 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_71557fd840694119bc0c6ca7711bec75 |
source | BMJ Open Access Journals |
subjects | Antigens Immunotherapy Lymphocytes Peptides Regular and Young Investigator Award Abstracts T cell receptors |
title | 192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A59%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_9YT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=192%E2%80%85Pooled%20T%20cell%20receptor%20screening%20(POTS)%20provides%20unbiased,%20high-throughput%20method%20for%20TCR%20discovery&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Reid,%20Jack&rft.date=2021-11-01&rft.volume=9&rft.issue=Suppl%202&rft.spage=A204&rft.epage=A204&rft.pages=A204-A204&rft.eissn=2051-1426&rft_id=info:doi/10.1136/jitc-2021-SITC2021.192&rft_dat=%3Cproquest_9YT%3E2595870566%3C/proquest_9YT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1852-41eba7e8455f13c82a4eb80501499b2ea3ed1c01816d9f434943fe9b12746b193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2595870566&rft_id=info:pmid/&rfr_iscdi=true |